associ
acut
viral
infect
respiratori
tract
exacerb
asthma
chronic
obstruct
pulmonari
diseas
copd
although
exacerb
associ
sever
type
virus
human
rhinovirus
hrv
associ
vast
major
diseas
exacerb
due
lack
anim
speci
natur
permiss
hrv
use
facil
model
system
limit
associ
anim
model
asthma
copd
studi
control
experiment
infect
human
hrv
use
conduct
safe
decad
review
discuss
experiment
infect
studi
hrv
provid
mean
understand
pathophysiolog
underli
virusinduc
exacerb
asthma
copd
goal
develop
agent
prevent
treatment
util
anim
vivo
experiment
infect
human
rhinovirus
develop
therapeut
agent
viral
exacerb
asthma
chronic
obstruct
pulmonari
diseas
purpos
review
discuss
util
experiment
infect
anim
human
human
rhinovirus
hrv
mean
understand
pathophysiolog
underli
virusinduc
exacerb
asthma
chronic
obstruct
pulmonari
diseas
copd
goal
develop
agent
prevent
treatment
asthma
copd
lead
caus
morbid
mortal
world
health
organ
estim
million
peopl
worldwid
asthma
associ
asthma
death
annual
addit
estim
copd
share
fourth
fifth
place
hivaid
coronari
heart
diseas
cerebrovascular
diseas
acut
respiratori
infect
singl
caus
death
copd
common
diseas
affect
million
patient
countri
us
japan
franc
germani
itali
uk
canada
third
lead
caus
death
us
cost
us
copd
project
approxim
billion
includ
direct
health
care
expenditur
indirect
morbid
indirect
mortal
cost
direct
cost
treat
copd
exacerb
alon
us
may
exceed
billion
asthma
character
presenc
revers
bronchoconstrict
increas
sensit
specif
nonspecif
bronchospast
agent
excess
mucu
product
accompani
underli
patholog
inflamm
associ
airway
remodel
diagnosi
asthma
classif
sever
primarili
base
upon
symptom
cough
wheez
short
breath
combin
assess
airflow
obstruct
level
control
observ
variou
therapeut
intervent
recent
data
asthma
clinic
research
network
suggest
approxim
half
patient
diagnos
mildtomoder
asthma
present
either
persist
intermitt
persist
eosinophil
phenotyp
respons
combin
antiinflammatori
therapi
remain
half
patient
present
persist
noneosinophil
asthma
phenotyp
lessrespons
similar
intervent
respect
sever
asthma
nation
heart
lung
blood
institut
sever
asthma
research
program
sarp
reveal
five
distinct
phenotyp
cluster
within
sever
asthma
highlight
heterogen
underli
molecular
cellular
physiolog
manifest
diseas
copd
debilit
chronic
respiratori
diseas
associ
cough
dyspnea
excess
sputum
product
progress
loss
lung
function
begin
emerg
middl
age
older
patient
cigarett
smoke
main
risk
factor
copd
addit
air
pollut
biofuel
occup
exposur
diagnosi
copd
base
present
symptom
chronic
cough
dyspnea
sputum
product
conjunct
spirometri
assess
postbronchodil
forc
expiratori
volum
sforc
vital
capac
fev
fvc
ratio
indic
copd
copd
may
present
heterogen
mixtur
physiolog
manifest
includ
chronic
bronchiti
parenchym
destruct
emphysema
exacerb
may
increas
hyperinfl
ga
trap
lead
reduct
airflow
enhanc
dyspnea
recent
adapt
global
initi
chronic
obstruct
lung
diseas
gold
assess
diseas
featur
combin
copd
assess
includ
associ
symptom
spirometr
classif
futur
risk
exacerb
subject
gold
grade
subject
exacerb
per
year
consid
high
risk
exacerb
research
sever
decad
shown
predispos
individu
associ
acut
viral
infect
respiratori
tract
exacerb
exist
chronic
pulmonari
condit
asthma
copd
virusinduc
exacerb
contribut
significantli
morbid
mortal
asthma
copd
effect
therapeut
intervent
exacerb
remain
major
unmet
medic
need
develop
agent
prevent
treat
exacerb
asthma
copd
remain
challeng
due
inher
heterogen
diseas
like
mediat
differ
inflammatori
pathway
andor
mechan
modul
genet
environment
factor
scenario
complic
possibl
addit
inflammatori
pathway
associ
diseas
exacerb
invok
virus
may
also
differ
differ
diseas
phenotyp
asthma
copd
complic
possibl
biolog
cascad
induc
differ
type
respiratori
virus
associ
exacerb
asthma
copd
may
differ
type
strain
viru
collect
present
extrem
complex
pathophysiolog
multipl
variabl
respect
translat
find
preclin
experi
anim
model
virusinduc
exacerb
context
asthma
copd
limit
rather
experiment
infect
healthi
adult
human
volunt
provid
much
understand
regard
biolog
hrv
infect
respiratori
virus
commonli
associ
pulmonari
exacerb
initi
hrv
challeng
studi
healthi
volunt
use
studi
develop
therapeut
common
cold
order
better
understand
underli
mechan
viru
induc
exacerb
asthma
copd
develop
agent
prevent
treat
studi
select
subject
popul
asthma
copd
challeng
character
viru
strain
recent
employ
build
experi
small
control
viral
challeng
intervent
studi
asthma
copd
earli
clinic
develop
could
help
triag
agent
potenti
attenu
manifest
naturallyacquir
hrv
infect
lead
diseas
exacerb
review
summar
common
respiratori
virus
role
play
acut
exacerb
airway
diseas
recent
advanc
hrv
challeng
studi
particular
emphasi
studi
conduct
subject
asthma
copd
upper
lower
respiratori
tract
infect
urti
lrti
caus
larg
number
differ
virus
multipl
viru
famili
virus
caus
similar
constel
clinic
symptom
gener
refer
cold
flu
symptom
vari
sever
depend
upon
type
viru
inher
pathogen
strain
host
age
immun
statu
comorbid
genet
background
virus
commonli
isol
respiratori
tract
sampl
collect
patient
present
cold
symptom
present
tabl
review
ref
us
alon
million
emerg
depart
visit
million
adult
million
children
age
year
asthma
hospit
adult
children
death
due
asthma
among
adult
among
children
mani
result
acut
respiratori
viral
infect
trigger
asthma
exacerb
overal
risk
death
patient
hospit
asthma
exacerb
us
us
million
emerg
depart
visit
adult
year
older
diagnos
copd
result
hospit
death
annual
rate
copd
exacerb
estim
rang
virusinduc
exacerb
result
diseas
worsen
requir
increas
pharmacolog
treatment
visit
emerg
room
hospit
admiss
intens
care
death
exampl
inhospit
mortal
rate
associ
acut
exacerb
copd
vari
markedli
studi
depend
upon
comorbid
mode
recruit
set
medic
ward
versu
intens
care
unit
sever
type
virus
associ
exacerb
asthma
copd
clear
multipl
studi
vast
major
virusinduc
exacerb
asthma
copd
caus
hrv
acut
exacerb
asthma
caus
hrv
respons
asthma
exacerb
children
exacerb
adult
factor
relat
host
viru
environ
associ
hrv
infect
asthma
detail
comprehens
recent
review
infect
hrv
link
exacerb
copd
although
human
respiratori
syncyti
viru
hrsv
human
parainfluenza
viru
hpiv
influenza
viru
also
recogn
agent
associ
exacerb
asthma
copd
hrv
first
isol
cultur
patient
cold
symptom
late
later
classifi
newli
discov
infecti
agent
hrv
subsequ
determin
member
enteroviru
genu
picornavirida
famili
nonenvelop
positivesens
singlestrand
rna
virus
type
hrv
character
classifi
group
hrva
hrvb
recent
hrvc
hrv
infect
occur
throughout
year
typic
hrv
infect
peak
spring
autumn
interestingli
individu
may
infect
sever
time
year
recurr
hrv
infect
may
due
misdirect
antibodi
respons
nonprotect
epitop
associ
capsid
protein
mechan
escap
result
lack
immunolog
protect
hrv
infect
hrv
typic
infect
upper
airway
nasal
mucosa
sinus
middl
ear
clinic
cours
infect
well
character
infect
produc
symptom
common
cold
sneez
nasal
congest
rhinorrhea
eye
irrit
sore
throat
cough
headach
fever
chill
healthi
individu
hrv
infect
gener
selflimit
typic
restrict
upper
airway
hrvinduc
cold
lead
caus
acut
morbid
miss
day
work
school
associ
nearli
children
year
age
particularli
children
histori
wheezingasthma
hrv
infect
also
lead
infect
lower
airway
otiti
media
particularli
young
children
sinus
certain
predispos
individu
diagnos
asthma
copd
inher
defici
innat
antivir
immun
respons
may
also
contribut
enhanc
suscept
hrv
infect
lead
acut
exacerb
diseas
initi
studi
focus
ex
vivo
assess
primari
bronchial
epitheli
cell
deriv
asthmat
subject
indic
abnorm
innat
respons
infect
specif
increas
viral
replic
cell
lysi
associ
resist
earli
apoptosi
hrv
infect
defici
type
interferon
ifnb
respons
subsequ
studi
demonstr
asthmat
subject
challeng
experienc
enhanc
lower
respiratori
symptom
bronchial
hyperreact
associ
greater
bronchoalveolar
lavag
bal
leukocyt
concentr
dysregul
ifng
respons
compar
normal
subject
certain
rare
circumst
hrv
infect
also
lead
seriou
complic
pneumonia
particularli
infant
young
children
children
underli
condit
bronchopulmonari
dysplasia
congenit
heart
diseas
prematur
neurolog
condit
rhinovirus
detect
children
adult
pneumonia
upper
respiratori
sputum
sampl
review
ref
howev
hrv
commonli
detect
subject
mild
respiratori
symptom
even
asymptomat
individu
role
rhinoviru
detect
upper
airway
caus
agent
viral
pneumonia
still
question
complic
scenario
hrv
often
found
togeth
pneumonia
pathogen
bacteria
patient
pneumonia
viralbacteri
pneumonia
poorer
respons
treatment
pneumonia
caus
singl
agent
certain
immunosuppress
bone
marrow
transplant
recipi
adult
hrv
associ
sever
diseas
although
gener
report
increas
risk
seriou
complic
due
rhinoviru
infect
popul
due
extens
sequenc
variat
among
differ
type
hrv
cocircul
multipl
type
recombin
subsequ
lack
broadli
cross
reactiv
antibodi
respons
develop
vaccin
hrv
repres
tremend
challeng
due
gener
mild
selflimit
natur
hrv
infect
healthi
adult
direct
antivir
agent
hrv
would
need
except
safe
littl
safeti
risk
use
popul
number
antivir
agent
specif
direct
hrv
eg
capsidbind
compound
proteas
inhibitor
inhibitor
receptor
clinic
trial
typic
shown
minim
efficaci
toxic
develop
termin
due
lack
accept
benefiterisk
profil
review
ref
current
treatment
rhinoviru
infect
palli
includ
antipyret
decongest
herbal
natur
supplementbas
treatment
eg
echinacea
ascorb
acid
vitamin
c
zinc
shown
clinic
effect
given
high
hurdl
hrv
antivir
widespread
use
counter
treatment
treat
symptom
surpris
direct
antivir
hrv
current
clinic
develop
clinicaltrialsgov
februari
greatest
unmet
need
specif
therapeut
agent
target
hrv
hrvassoci
inflamm
prevent
treatment
acut
viral
exacerb
asthma
copd
develop
prevent
vaccin
hrv
remain
signific
challeng
recent
effort
toward
develop
specif
therapeut
agent
treat
prevent
hrvinduc
exacerb
shift
focu
defin
underli
mechan
associ
virusinduc
exacerb
includ
improv
inher
defici
innat
host
antivir
defens
atrisk
popul
reduc
excess
inappropri
inflammatori
host
immun
respons
trigger
hrv
context
activ
pulmonari
diseas
addit
effort
focus
direct
act
antihrv
antivir
therapeut
intervent
sever
virus
rhinovirus
includ
human
respiratori
syncyti
viru
hrsv
influenza
human
coronaviru
hcov
enterovirus
ev
human
parainfluenza
virus
hpiv
human
adenovirus
adv
human
bocaviru
hbov
also
associ
exacerb
asthma
copd
found
less
frequent
hrv
predomin
exacerb
agent
vari
depend
upon
individu
age
geograph
locat
season
unknown
biolog
cascad
induc
infect
differ
type
respiratori
virus
associ
exacerb
asthma
copd
similar
differ
type
strain
viru
pictur
complic
differ
cell
tropism
variou
form
cytopatholog
caus
type
viru
even
differ
strain
viru
one
key
issu
hamper
use
anim
model
studi
infect
human
respiratori
virus
fact
nonhuman
speci
except
chimpanze
partial
permiss
best
infect
almost
human
respiratori
virus
includ
rhinoviru
note
except
influenza
viru
natur
cross
infect
divers
speci
eg
pig
bird
human
hrv
exquisit
speciesspecif
nonhuman
primat
abl
product
infect
major
class
hrv
chimpanze
although
gibbon
also
report
abl
infect
chimpanze
endang
speci
restrict
place
research
chimpanze
make
use
unrealist
base
ethic
reason
current
unit
state
gabon
countri
allow
medic
research
conduct
chimpanze
us
nation
institut
health
recent
reassess
use
chimpanze
medic
research
intent
elimin
use
favor
altern
model
addit
systemat
review
use
chimpanze
monoclon
antibodi
drug
develop
encompass
almost
decad
continu
identifi
key
differ
human
chimpanze
immun
function
highlight
difficulti
predict
result
human
patient
base
data
chimpanze
support
fact
although
chimpanze
product
infect
hrv
develop
clinic
symptom
associ
common
cold
addit
speci
gibbon
list
endang
critic
endang
gibbon
also
report
develop
cold
symptom
attempt
infect
vervet
monkey
wide
varieti
primat
speci
hrv
unsuccess
due
fact
approxim
hrv
previous
design
major
group
hrv
use
human
intracellular
adhes
molecul
receptor
infect
cell
major
group
hrv
abl
use
human
chimpanze
origin
convers
minorgroup
rhinovirus
bind
member
lowdens
lipoprotein
receptor
famili
share
mous
human
infect
minorgroup
balbc
mice
shown
elicit
acut
influx
inflammatori
cell
type
includ
neutrophil
lymphocyt
neutrophil
tcellassoci
chemokin
type
type
ii
viralassoci
ifn
respons
mucin
product
howev
hrv
belong
minor
group
repres
approxim
known
hrv
address
issu
recent
effort
group
focus
develop
transgen
mice
engin
express
chimer
murinehuman
work
demonstr
human
chimer
icam
transgen
mice
balbc
background
infect
result
similar
observ
minor
group
wild
type
mice
certainli
differ
hrv
infect
human
chimer
icam
transgen
mous
model
respect
correl
clinic
paramet
relat
cold
symptom
model
use
assess
impact
rhinoviru
exacerb
allerg
diseas
combin
ovalbumin
model
allerg
airway
inflamm
subsequ
work
sinc
demonstr
util
test
antihuman
antibodi
bind
domain
human
model
result
reduct
level
cellular
inflamm
cytokin
product
associ
rhinoviru
infect
addit
reduct
viral
load
rel
baselin
preinfect
isotyp
control
postinfect
anim
model
hrv
infect
exacerb
caus
hrv
valu
assess
specif
mechan
may
associ
viral
exacerb
human
complic
sever
issu
lack
clinic
symptom
reflect
infect
human
differ
physiolog
respiratori
tract
human
speci
typic
use
preclin
studi
mous
branch
occur
bronchiol
level
addit
sinc
anim
mice
natur
develop
asthma
copd
underli
baselin
inflammatori
profil
acut
patholog
mice
develop
respons
viral
challeng
experiment
model
may
complet
reflect
human
diseas
coupl
inabl
speci
natur
infect
hrv
human
viral
respiratori
pathogen
high
titer
viral
inoculum
requir
infect
gener
infecti
dose
tissu
cultur
tcid
versu
tcid
human
minim
replic
viru
make
model
less
ideal
studi
virusinduc
exacerb
asthma
copd
translat
observ
vivo
anim
model
human
diseas
respect
assess
potenti
candid
therapeut
intervent
remain
clinic
valid
reason
experiment
infect
human
hrv
control
challeng
model
may
greater
util
develop
therapeut
agent
intercept
treat
viral
exacerb
asthma
copd
hrv
infect
human
subject
includ
asthma
copd
studi
observ
manner
natur
occur
wild
type
respiratori
viral
infect
use
experiment
infect
control
viral
challeng
studi
control
experiment
infect
studi
sever
advantag
natur
wild
type
observ
studi
includ
control
clinic
set
defin
subject
popul
use
character
inoculum
regard
strain
serotyp
use
uniform
challeng
dose
uniform
time
infect
exclus
identif
coinfect
respiratori
virus
plan
detail
biospecimen
collect
observ
followup
context
control
clinic
set
also
possibl
develop
therapeut
agent
intercept
treat
hrv
induc
exacerb
experiment
infect
studi
also
benefit
allow
select
small
focus
popul
minim
number
subject
expos
novel
agent
may
limit
data
respect
riskebenefit
profil
sinc
initi
isol
identif
numer
experiment
infect
studi
hrv
safe
conduct
healthi
adult
subject
well
asthmaticand
recent
copdsubject
popul
year
guidelin
develop
safeti
test
suitabl
rhinoviru
challeng
stock
manufactur
character
accord
good
manufactur
practic
gmp
standard
initi
avail
earli
although
challeng
pool
use
studi
meet
standard
sinc
guidelin
updat
gmpprepar
stock
requir
regul
experiment
infect
studi
human
control
experiment
infect
studi
also
includ
measur
limit
spread
viru
studi
personnel
other
studi
evid
spread
infect
personnel
conduct
studi
due
lack
permiss
anim
speci
much
understand
clinic
cours
hrv
infect
deriv
experiment
infect
healthi
human
volunt
sinc
initi
isol
character
hrv
numer
studi
conduct
adult
healthi
subject
understand
basic
biolog
hrv
infect
includ
clinic
symptom
natur
cours
infect
host
immun
respons
infect
persontoperson
transmiss
addit
experiment
infect
studi
also
use
evalu
potenti
agent
intend
prevent
andor
treatment
common
cold
experiment
infect
healthi
adult
subject
inocul
intranas
tcid
rhinoviru
commonli
cours
infect
observ
approxim
week
seriou
advers
event
eg
pneumonia
report
studi
healthi
adult
subject
experiment
infect
selflimit
observ
natur
occur
hrv
infect
experiment
viral
challeng
studi
atop
mild
moder
asthmat
subject
inocul
defin
hrv
stock
effort
elicit
product
respiratori
infect
typic
induc
respiratori
symptom
similar
observ
mild
acut
exacerb
atop
mild
asthmat
includ
lower
respiratori
symptom
airflow
obstruct
chang
peak
expiratori
flow
pef
system
airway
inflamm
greater
prolong
compar
control
gener
nonasthmat
healthi
subject
group
studi
use
surrog
clinic
model
natur
occur
rhinovirusinduc
exacerb
airway
diseas
sever
asthma
mean
provid
greater
insight
underli
mechan
host
respons
respiratori
viral
infect
asthmat
compar
healthi
individu
conduct
experiment
hrv
challeng
studi
subject
asthma
copd
subject
safeti
utmost
concern
minim
risk
studi
typic
enrol
subject
mild
moder
stabl
diseas
exclud
poor
lung
function
poorli
control
diseas
histori
recent
hospit
due
exacerb
experiment
hrv
infect
studi
complet
date
quit
help
defin
underli
mechan
associ
host
respons
hrv
infect
howev
magnitud
symptom
experiment
infect
studi
less
mark
natur
occur
exacerb
patient
sever
diseas
difficult
detect
signific
treatment
effect
assess
potenti
therapeut
candid
studi
initi
studi
asthmat
subject
design
similar
fashion
experiment
infect
healthi
subject
atop
mild
asthmat
subject
inocul
intranas
tcid
hrv
commonli
clinic
symptom
lung
function
biomark
host
immun
respons
data
collect
experiment
viral
challeng
studi
infect
gener
well
toler
subject
experienc
clinic
symptom
common
cold
similar
observ
healthi
control
subject
experienc
increas
chest
symptom
eg
cough
phlegm
product
wheez
compar
healthi
subject
subject
mild
moder
asthma
exhibit
enhanc
host
immun
respons
viral
challeng
includ
increas
bal
lymphocyt
concentr
enhanc
lower
respiratori
symptom
typic
viral
replic
peak
day
post
infect
local
inflammatori
respons
symptom
peak
day
post
infect
atop
individu
mild
asthmat
subject
lung
function
appear
impair
signific
degre
howev
studi
pronounc
effect
upon
lung
function
eg
statist
signific
decreas
fev
pef
observ
major
studi
perform
mild
asthmat
reduc
potenti
induc
sever
acut
exacerb
limit
number
studi
also
incorpor
allergen
challeng
togeth
hrv
infect
atop
asthmat
subject
provok
inflammatori
respons
associ
exacerb
context
allerg
respons
relev
allergen
even
dual
provoc
studi
could
result
amplifi
respons
report
clinic
exacerb
need
medic
intervent
rare
one
allergenrv
challeng
studi
subject
withdrew
due
asthma
exacerb
one
subject
spontan
exacerb
placeboallergen
period
prior
infect
anoth
subject
develop
hrvinduc
exacerb
second
day
inocul
high
dose
tcid
week
exposur
allergen
hous
dust
mite
extract
subject
pef
decreas
person
best
subject
withdrawn
studi
admit
hospit
singl
night
treat
oxygen
inhal
ipratropiumsalbutamol
oral
prednison
recov
quickli
night
follow
day
intervent
studi
use
hrv
challeng
asthmat
limit
number
assess
impact
steroid
therapi
hrv
infect
asthma
mild
asthmat
experiment
infect
treat
inhal
corticosteroid
budesonid
mg
twice
day
week
start
week
prior
infect
worsen
airway
inflamm
base
induc
sputum
asthmat
subject
observ
subsequ
studi
asthmat
male
subject
random
receiv
oral
prednison
mg
placebo
time
day
day
steroid
treatment
initi
h
prior
inocul
hrv
safeti
concern
report
suggest
treatment
prednison
impair
host
respons
hrv
infect
recent
preliminari
studi
experiment
infect
moder
asthmat
subject
alreadi
receiv
inhal
corticosteroid
ic
safeti
concern
withdraw
due
safeti
issu
seriou
advers
event
requir
treatment
beyond
extra
bronchodil
use
report
respons
hrv
infect
measur
cold
symptom
asthma
score
similar
previous
observ
subject
receiv
ic
therapi
host
respons
measur
protein
sputum
nasal
lavag
also
similar
interestingli
even
popul
moder
asthmat
decrement
lung
function
observ
although
may
due
increas
bronchodil
use
studi
collect
studi
indic
even
context
immunosuppress
associ
corticosteroid
experiment
hrv
infect
safe
well
toler
asthmat
subject
furthermor
experiment
hrv
infect
rel
safe
use
tool
defin
underli
immun
mechan
associ
hrvinduc
diseas
exacerb
appli
intervent
studi
hrv
infect
lead
viral
caus
copd
exacerb
experiment
infect
copd
subject
also
use
model
better
understand
underli
biolog
copd
exacerb
recent
emerg
seri
experiment
challeng
studi
perform
subject
mild
moder
diseas
focus
examin
underli
mechan
hrvinduc
exacerb
copd
initi
studi
mallia
et
al
employ
dose
escal
approach
determin
minimum
dose
requir
product
infect
gold
stage
ii
moder
copd
subject
addit
assess
safeti
paramet
establish
model
new
popul
follow
studi
address
impact
smoke
also
mechanist
question
relat
host
immun
respons
copd
compar
subject
copd
control
subject
nonobstruct
subject
similar
smoke
histori
normal
lung
function
demonstr
subject
copd
exhibit
increas
upper
lower
respiratori
symptom
score
reduc
postbronchodil
pef
increas
viral
load
nasal
lavag
sputum
increas
inflammatori
marker
rel
baselin
valu
compar
control
subject
follow
experiment
infect
daili
upper
respiratori
symptom
score
peak
earlier
day
copd
subject
lower
respiratori
symptom
score
peak
later
day
peak
expiratori
flow
trough
observ
day
peak
viral
titer
delay
somewhat
rel
observ
asthmat
day
howev
lower
inoculum
tcid
employ
studi
may
result
longer
period
time
reach
peak
viral
titer
addit
investig
provid
insight
secondari
bacteri
infect
follow
rhinoviru
infect
develop
averag
day
postinocul
approxim
copd
subject
observ
smoke
nonsmok
control
subject
data
highlight
frequenc
secondari
bacteri
infect
copd
suggest
potenti
impact
earlier
intervent
antivir
therapi
reduc
primari
viralinduc
copd
exacerb
complic
associ
potenti
secondari
bacteri
infect
evalu
lymphocyt
subset
show
lower
frequenc
cell
peripheri
increas
frequenc
bal
copd
subject
rel
control
also
differ
neutrophil
adhes
activ
marker
copd
subject
rel
control
subject
follow
infect
overal
experiment
hrv
infect
well
toler
without
seriou
advers
event
copd
control
popul
addit
work
explor
specif
compon
host
innat
immun
respons
acut
infect
may
help
provid
insight
associ
sever
acut
viralexacerb
copd
specif
clinic
phenotyp
diseas
assess
variou
biomark
profil
airway
peripher
blood
may
help
defin
host
immun
respons
hrv
infect
provid
insight
differ
mechan
suscept
virusinduc
exacerb
may
associ
underli
heterogen
observ
asthma
copd
also
assess
potenti
efficaci
therapeut
compound
clinic
develop
prevent
intervent
acut
viral
exacerb
respiratori
diseas
signific
work
done
date
use
vitro
system
assess
impact
hrv
infect
primari
cell
deriv
subject
asthma
copd
defin
specif
mechanist
compon
host
innat
respons
cellular
level
work
critic
guid
potenti
biomark
work
subsequ
experiment
viral
challeng
studi
human
recent
advanc
propag
human
rhinovirusc
hrvc
human
sinu
airway
cell
differenti
airliquid
interfac
ali
provid
mean
studi
addit
relev
hrv
strain
beyond
serotyp
use
date
potenti
provid
path
forward
evalu
host
respons
hrvc
experiment
challeng
model
human
addit
natur
occur
hrv
infect
human
provid
addit
although
retrospect
data
defin
host
immun
respons
acut
hrv
infect
serum
interferoninduc
protein
demonstr
biomark
associ
hrv
infect
copd
also
suggest
potenti
biomark
asthma
base
vitro
experi
assess
acut
natur
occur
infect
asthmat
experiment
hrv
infect
studi
enabl
broad
assess
host
respons
biomark
specif
defin
time
period
context
wellcontrol
studi
respect
viral
challeng
pool
studi
popul
typic
peak
hrv
concentr
nasal
wash
specimen
detect
day
post
infect
recoveri
replic
viru
indic
product
infect
recov
nasal
wash
provid
mean
assess
impact
therapeut
intervent
viral
replic
kinet
cold
symptom
score
increas
peak
day
post
infect
relat
patientreport
outcom
asthma
control
questionnair
act
score
tend
lag
behind
peak
day
post
infect
assess
underli
biomark
associ
hostanti
viral
respons
tend
peak
day
remain
elev
sever
day
prior
recoveri
protein
level
demonstr
strong
associ
respons
time
nasal
lavag
airway
sputum
sampl
biomark
interest
also
identifi
human
experiment
hrv
challeng
studi
exampl
polymorph
interleukin
promot
posit
associ
greater
symptom
magnitud
context
experiment
infect
assess
differenti
gene
express
profil
deriv
nasal
scrape
preand
posthrv
infect
indic
signific
chang
chemokin
signal
molecul
interferonrespons
gene
antivir
viperin
express
associ
product
hrv
infect
addit
experiment
rhinoviru
infect
associ
increas
human
tissu
kallikrein
activ
allerg
subject
biomark
perspect
experiment
viral
challeng
studi
provid
distinct
advantag
follow
natur
occur
hrv
infect
time
abil
assess
acut
host
respons
infect
focus
control
manner
use
specif
character
inoculum
uniform
challeng
dose
provid
mean
comprehens
assess
innat
adapt
immun
respons
multipl
biolog
matric
transcriptom
proteom
level
includ
baselin
preinfect
acut
infect
also
convalesc
follow
period
addit
subject
specif
predefin
clinic
phenotyp
may
recruit
help
elucid
potenti
differ
mechan
suscept
associ
virusinduc
exacerb
compar
broader
heterogen
popul
recent
advanc
transcriptom
proteom
platform
addit
advanc
comput
biolog
approach
build
experimentallydefin
network
diseas
may
help
provid
addit
tool
better
understand
relationship
acut
viral
exacerb
asthma
copd
rhinoviru
infect
date
approv
vaccin
antivir
agent
prevent
treat
hrv
infect
review
ref
result
clinic
studi
direct
act
antivir
pleconaril
show
day
reduct
median
time
allevi
clinic
ill
compar
placebo
studi
examin
effect
pleconaril
cold
symptom
asthma
exacerb
follow
hrv
exposur
complet
result
post
clinicaltrialsgov
indic
compar
placebo
treatment
pleconaril
associ
statist
signific
effect
p
percentag
hrvposit
subject
asthma
exacerb
collect
result
suggest
treatment
antivir
alon
may
suffici
infect
rhinoviru
associ
upper
respiratori
immunemedi
inflamm
sever
studi
examin
effect
either
prophylaxi
treatment
broad
act
antiinflammatori
agent
specif
corticosteroid
administ
either
system
inhal
experiment
rhinoviru
infect
corticosteroid
broadli
inhibit
immunemedi
eg
cytokin
chemokin
cellmedi
inflammatori
respons
one
studi
effect
combin
intranas
system
corticosteroid
local
inflammatori
respons
symptom
due
experiment
rhinoviru
infect
healthi
adult
examin
studi
adult
random
prophylaxi
either
placebo
steroid
intranas
beclomethason
mg
twice
day
initi
day
viral
challeng
continu
day
challeng
oral
prednison
mg
twice
daili
given
day
start
day
prior
challeng
first
h
viral
inocul
nasal
obstruct
nasal
mucu
weight
kinin
concentr
nasal
lavag
lower
steroid
recipi
subsequ
increas
variabl
steroid
group
result
signific
cumul
differ
treatment
group
data
suggest
steroid
prophylaxi
may
suppress
nasal
inflamm
cold
symptom
first
day
experiment
rhinoviru
cold
advers
event
ae
seriou
advers
event
sae
report
recent
emerg
data
highlight
impact
rhinoviru
infect
steroid
respons
airway
epitheli
ex
vivo
cell
base
system
infect
impair
dexamethasonedepend
inhibit
releas
induct
mitogenactiv
protein
kinas
phosphatas
gene
express
bind
gr
gre
airway
epitheli
cell
indic
infect
human
airway
epithelium
induc
glucocorticoid
resist
given
larg
use
daili
clinic
practic
inhaledsystem
corticosteroid
viralinduc
exacerb
pro
con
therapeut
intervent
corticosteroid
must
consid
context
specif
clinic
present
kloepfer
colleagu
conduct
random
doubleblind
placebocontrol
trial
mild
allerg
asthmat
assess
efficaci
montelukast
leukotrien
receptor
antagonist
lessen
asthma
symptom
follow
experiment
inocul
popul
subject
activ
placebo
subject
montelukast
leukotrien
receptor
antagonist
appear
signific
impact
asthma
control
cold
symptom
score
caus
experiment
rhinoviru
infect
patient
experiment
infect
octob
search
clinicaltrialsgov
use
keyword
rhinoviru
identifi
asthma
exacerb
studi
subject
experiment
infect
treat
antiinflammatori
agent
mepolizumab
monoclon
antibodi
cnto
monoclon
antibodi
direct
innat
immun
respons
target
studi
examin
abil
antiinflammatori
agent
allevi
hrvinduc
effect
asthma
symptom
pulmonari
function
although
initi
identifi
agent
common
cold
hrv
signific
human
pathogen
associ
signific
respiratori
ill
bronchiol
pneumonia
predomin
viru
associ
acut
exacerb
asthma
copd
virusinduc
exacerb
asthma
copd
result
complex
interact
multitud
variabl
make
develop
agent
prevent
treat
exacerb
tremend
challeng
variabl
aris
number
factor
includ
infect
viru
type
viru
particular
strain
time
infect
inoculum
size
hostrel
factor
genet
phenotyp
asthma
prior
infect
immun
responseimmun
inher
microbi
flora
host
medic
histori
eg
comorbid
concomit
medic
environment
condit
eg
aeroallergen
due
lack
anim
speci
natur
permiss
hrv
use
facil
model
system
coupl
limit
associ
anim
model
asthma
copd
experiment
infect
studi
human
crucial
understand
biolog
hrv
pathogenesi
control
natur
hrv
challeng
studi
help
allevi
much
variabl
associ
studi
natur
occur
diseas
exacerb
experiment
infect
studi
focus
tri
understand
immunemedi
inflammatori
respons
ie
cytokin
chemokin
mediat
cell
type
signal
pathway
hrv
infect
asthmat
patient
copd
often
compar
respons
healthi
affect
popul
respons
among
patient
differ
sever
diseas
addit
although
develop
gmp
manufactur
hrv
challeng
stock
trivial
experiment
infect
serotyp
hrv
critic
determin
result
obtain
isol
use
frequent
extend
serotyp
hrvc
group
may
relev
group
individu
asthma
experiment
challeng
studi
subject
specif
predefin
clinic
phenotyp
associ
asthma
copd
may
help
elucid
potenti
differ
mechan
suscept
associ
virusinduc
exacerb
compar
broader
heterogen
popul
experiment
hrv
infect
studi
conduct
safe
normal
subject
chronic
respiratori
diseas
asthma
copd
although
hrv
associ
seriou
complic
pneumonia
sever
immunosuppress
individu
bone
marrow
transplant
recipi
report
pneumonia
seriou
complic
publish
studi
experiment
infect
hrv
healthi
adult
subject
mild
moder
asthma
subject
copd
even
context
inhal
system
corticosteroid
experiment
infect
studi
hrv
crucial
understand
underli
molecular
mechan
involv
acut
exacerb
asthma
copd
trigger
hrv
infect
essenti
develop
agent
prevent
treat
exacerb
recent
advanc
transcriptom
proteom
platform
addit
advanc
comput
biolog
approach
build
experimentallydefin
network
diseas
may
also
help
defin
potenti
point
intercept
either
repair
inher
defici
innat
antivir
immun
respons
reduc
exagger
host
respons
acut
viral
infect
